Market Access News | pharmaphorum

News

abstract shapes, bone structure, 3d render, bone

NICE ends UK access disparity to osteoporosis drug Evenity

NICE has reversed its stance on UCB and Amgen's severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high

News

Patients dismayed as FDA advisors narrowly reject Amylyx' AL...

By a narrow margin, an FDA advisory committee has voted against approval of Amylyx' experimental medicine for amyotrophic lateral sclerosis until the company can provide more evidence that

News

Amylyx slumps on non-committal FDA reviewer assessment of AL...

Shares in Amylyx Pharma slid today after the FDA published a less-than-enthusiastic assessment of its amyotrophic lateral sclerosis (ALS) therapy ahead of an advisory committee meeting on W

News

FDA restricts GSK's Xevudy due to lower efficacy against BA....

GlaxoSmithKline and Vir's Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus.

News

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA's human medicines commi

News

ViiV, J&J get FDA nod for simpler HIV injectable dosing

The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for their Cabenuva product that does away wit

NICE ends UK access disparity to osteoporosis drug Evenity

Patients dismayed as FDA advisors narrowly reject Amylyx' AL...

Amylyx slumps on non-committal FDA reviewer assessment of AL...

FDA restricts GSK's Xevudy due to lower efficacy against BA....

CHMP backs J&J's myeloma CAR-T therapy Carvykti

ViiV, J&J get FDA nod for simpler HIV injectable dosing

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks